Aptuit, Inc. Bookmark and Share

ArticleDateSource
Aptuit and Aegerion Sign Commercial API Supply AgreementJanuary 08, 2013Pharma News - PR Newswire
Aptuit LLC Names Stuart E. Needleman as President and Chief Operating OfficerMarch 15, 2012Pharma News - PharmiWeb
Aptuit Appoints COOMarch 15, 2012Contract Pharma
Samenvatting: Catalent rond overname af van Aptuit LLCFebruary 20, 2012Pharma News - Business Wire
Resumen: Catalent completa la adquisición de la actividad de Materiales para Ensayos Clínicos de Aptuit LLCFebruary 20, 2012Pharma News - Business Wire
Aptuit Completes Sale of CTS to Catalent; Reinforces Commitment to Scientific Excellence and Most Comprehensive Early to Mid-Phase Development CapabilityFebruary 17, 2012Biotech News - PR Newswire
Catalent Completes Acquisition of Clinical Trials Supplies Business of Aptuit LLCFebruary 17, 2012Pharma News - Business Wire
Catalent finalise son acquisition de l’activité Fournitures pour essais cliniques d’Aptuit LLCFebruary 17, 2012Pharma News - Business Wire
Catalent schließt Übernahme des Zulieferungsgeschäfts für klinische Studien von Aptuit LLC abFebruary 17, 2012Pharma News - Business Wire
Riassunto: Catalent completa l’acquisizione dell’attività Clinical Trials Supplies di Aptuit LLCFebruary 17, 2012Pharma News - Business Wire
<b>Fidelity Growth Partners India</b> Leads a $40 Million Investment Round in <b>Aptuit Laurus Private Limited</b> February 14, 2012BioSpace - Breaking News
Aptuit Names CSOOctober 06, 2011Contract Pharma
Catalent Pharma Solutions Reaches Agreement to Acquire Aptuit LLC's Clinical Trial Supplies BusinessSeptember 10, 2011Pharmaceutical - Moreover
Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix Nanotechnology PlatformMay 06, 2011Pharmaceutical - Moreover
Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix(TM) Nanotechnology PlatformMay 04, 2011Pharmaceutical - Moreover
Iroko Selects Aptuit as Contract Manufacturing Partner for Phase III Lower-Dose NSAID Programs Formulated Using the SoluMatrix™ Nanotechnology PlatformMay 04, 2011Pharma News - Business Wire
Scottish First Minister seeks talks with Aptuit over plant closuresDecember 21, 2010Pharmaceutical - Moreover
Aptuit threatens to chop hundreds of jobs in Scottish plant closuresDecember 16, 2010Pharmaceutical - Moreover
Aptuit To Cut Pharmaceutical Jobs In ScotlandDecember 14, 2010Pharmaceutical - Moreover
340 jobs face axe at drugs firm: Aptuit factory closures to hit hundredsDecember 11, 2010Pharmaceutical - Moreover
Aptuit and Exelixis Receive 2010 Scrip Award for Outsourcing Partnership Deal of the YearNovember 09, 2010Pharma News - Business Wire
GSK And Aptuit Finalize Agreement For Aptuit To Acquire GSKâs Research Operations In ItalyAugust 05, 2010Pharmaceutical - Moreover
Aptuit and Siena Biotech Announce Strategic Relationship in ItalyJuly 29, 2010Pharma News - Business Wire
Aptuit e Siena Biotech annunciano una collaborazione strategica in ItaliaJuly 29, 2010Pharma News - Business Wire
Aptuit Acquires GlaxoSmithKline’s Research
Operations in ItalyJuly 13, 2010CenterWatch - Clinical Trials
GSK and Aptuit finalise agreement for Aptuit to acquire GSK’s research operations in ItalyJuly 02, 2010Pharma News - PharmiWeb
GSK And Aptuit Finalize Agreement For Aptuit To Acquire GSKs Research Operations In ItalyJuly 01, 2010Pharmaceutical - Moreover
Aptuit agrees to acquire GSK research operationJuly 01, 2010Pharmaceutical - Moreover
Aptuit Acquires GSK Research SiteJuly 01, 2010Contract Pharma
GSK and Aptuit finalize agreement for Aptuit to acquire GSK’s research operations in ItalyJuly 01, 2010Pharma News - Business Wire
Aptuit Responds to Recent Media Coverage Regarding Its Offering in IndiaMarch 25, 2010Pharma News - Business Wire
Swiss Lonza Group Ltd. (LZAGY.PK) Eyes Stake in India Drug Firm, Aptuit Laurus in Deal Valued at $77 Million to $March 25, 2010Biotechnology - Moreover
Swiss Lonza Eyes Stake in India Drug Firm, Aptuit Laurus in Deal Valued at $77 Million to $March 24, 2010Biotechnology - Moreover
Aptuit Develops Advanced Solid-State Chemistry Production Screen to Address Challenges in the Drug Development Process 2/22/10February 25, 2010Pharmaceutical - Moreover
Aptuit unveils new solid state chemistry screenFebruary 18, 2010Pharmaceutical - Moreover
Aptuit Develops Advanced Solid-State Chemistry Production Screen to Address Challenges in the Drug Development ProcessFebruary 17, 2010Pharma News - Business Wire
Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare ConferenceJanuary 14, 2010Biotech News - PR Newswire
Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterization of Drug CompoundsPharma News - Business Wire



View all the latest news